Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NQO2 antisense RNA 1 (NQO2-AS1) is a long non-coding RNA transcribed from the antisense strand overlapping the NQO2 (NAD(P)H quinone dehydrogenase 2) gene locus. Antisense RNAs, including NQO2-AS1, are important regulators of gene expression through multiple mechanisms, both in *cis* (affecting the overlapping or nearby gene on the same DNA molecule) and *trans* (affecting distant loci). They can modulate transcription by altering chromatin states, promoter usage, or by directly binding to sense transcripts and influencing RNA processing or stability[2]. The specific biological function, disease involvement, or pharmacological targeting of NQO2-AS1 has not been reported; therefore, it is not considered a classical drug target, receptor, or enzyme at this time[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NQO2 antisense RNA 1 (NQO2-AS1).